

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

The board of directors' report on events of material significance pursuant to Chapter 14, Section 8 of the Swedish Companies Act (2005:551)

Since the presentation of the annual report for the financial year 2020/2021 for EQL Pharma AB, Reg. No. 556713-3425 (the "**Company**"), no events of material significance for the Company's financial position have occurred except as set out in the Company's interim report for the period 1 April – 30 September 2021 and subsequently issued press releases. The interim report and press releases are available at the Company's website, www.eqlpharma.com.

Lund on 23 November 2021

(Signature page follows)

The board of directors of EQL Pharma AB (publ)

Anders Månsson
(Chairman)

Christer Fåhraeus

Per Ollermark

Per Svangren

Rajiv I. Modi

Linda Neckmar